🇺🇸 FDA

Company profile · Sponsor

Akebia

Akebia Europe Limited

AKBA · NYSE pharma CAMBRIDGE, MA, GB
Pipeline
24
Drugs
2
Patents
8

Quick answer

Akebia (AKBA) is a pharma company. headquartered in CAMBRIDGE, MA, GB. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 2 drugs, and 8 patents to this profile..

Company facts

Ticker AKBA
Exchange NYSE
Company type pharma
Headquarters CAMBRIDGE, MA, GB
SEC CIK 0001517022

Pipeline (24)

Search pipeline →

  1. Epoetin alga (Epogen)/vadadustat

    Akebia

    Anemia Associated With Chronic Kidney Disease

    phase 3 small molecule active

    1 trial

  2. Erythropoiesis-Stimulating Agent (ESA)

    Akebia

    Anemia of Chronic Kidney Disease

    phase 3 small molecule active

    1 trial

  3. Ferric Citrate 1 GM Oral Tablet [AURYXIA]

    Akebia

    Anemia, Iron Deficiency

    phase 3 small molecule completed

    1 trial

  4. Vadadustat

    Akebia

    Anemia

    phase 3 small molecule completed

    10 trials

  5. Vadadustat

    Akebia

    Anemia Associated With Chronic Kidney Disease (CKD)

    phase 3 small molecule completed

    1 trial

  6. Vadadustat

    Akebia

    Anemia of Chronic Kidney Disease

    phase 3 small molecule active

    3 trials

  7. Vadadustat 900mg

    Akebia

    Nonintubated Acute Respiratory Distress Syndrome (ARDS)

    phase 3 small molecule active

    1 trial

  8. AKB-6548

    Akebia

    Anemia

    phase 2 small molecule completed

    4 trials

  9. IW-1973

    Akebia

    Type 2 Diabetes Mellitus With Diabetic Nephropathy

    phase 2 small molecule completed

    1 trial

  10. IW-1973

    Akebia

    Heart Failure With Preserved Ejection Fraction

    phase 2 small molecule completed

    1 trial

  11. Praliciguat

    Akebia

    Focal Segmental Glomerulosclerosis

    phase 2 small molecule active

    1 trial

  12. Vadadustat

    Akebia

    Chronic Kidney Disease

    phase 2 small molecule completed

    1 trial

  13. vadadustat

    Akebia

    Acute Respiratory Distress Syndrome

    phase 2 small molecule completed

    1 trial

  14. AKB-6548

    Akebia

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  15. AKB-6548 (therapeutic dose)

    Akebia

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  16. AKB-6548 tablet, reference formulation given in the fasted state

    Akebia

    Healthy

    phase 1 small molecule completed

    1 trial

  17. AKB-9090

    Akebia

    Healthy Volunteers

    phase 1 small molecule active

    1 trial

  18. Celecoxib

    Akebia

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  19. Vadadustat

    Akebia

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  20. Vadadustat

    Akebia

    Anemia Associated With Chronic Kidney Disease

    phase 1 small molecule completed

    1 trial

  21. Vadadustat

    Akebia

    Drug Interaction Potentiation

    phase 1 small molecule completed

    4 trials

  22. Vadadustat

    Akebia

    Hepatic Impairment

    phase 1 small molecule completed

    1 trial

  23. vadadustat

    Akebia

    Healthy

    phase 1 small molecule completed

    1 trial

  24. vadadustat reference tablets

    Akebia

    Healthy

    phase 1 small molecule completed

    1 trial

Drugs (2)

Search drugs →

  1. ferric citrate coordination complex

    XOANACYL

    V03AE08

  2. vadadustat

    VAFSEO

    ORAL approved

Patents (8)

Search patents →

  1. US 12419877

    Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11883386

    Prolyl hydroxylase inhibitors and methods of use

    Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11857543

    Compositions and methods for treating anemia

    Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11844756

    Compositions and methods for treating anemia

    Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11690836

    Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof

    Expires Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11524939

    Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid

    Expires Mon Dec 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11426393

    Prolyl hydroxylase inhibitors and methods of use

    Expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11324734

    Compositions and methods for treating anemia

    Expires Mon May 05 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Akebia?

Akebia (AKBA) is a pharma company. headquartered in CAMBRIDGE, MA, GB. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 2 drugs, and 8 patents to this profile..

What pipeline programs does Akebia sponsor?

We track 24 ClinicalTrials.gov-linked programs for Akebia, including Epoetin alga (Epogen)/vadadustat and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Akebia company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.